<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Setmelanotide: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Setmelanotide: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Setmelanotide: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="130245" href="/d/html/130245.html" rel="external">see "Setmelanotide: Drug information"</a> and <a class="drug drug_patient" data-topicid="130309" href="/d/html/130309.html" rel="external">see "Setmelanotide: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F55317407"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Imcivree</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F58519046"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Imcivree</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F55150511"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Melanocortin Receptor Agonist</span></li></ul></div>
<div class="block dop drugH1Div" id="F55173081"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="24267291-50a0-4efc-98cd-a5840a223299">Weight management, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Weight management, chronic:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For use <b>only</b> in patients with obesity due to Bardet-Biedl syndrome (BSS) or genetically confirmed or suspected proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years to &lt;12 years: SUBQ: Initial: 1 mg once daily for 2 weeks, then adjust dosage based on efficacy and tolerability as follows:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Additional weight loss desired</i>: Increase dose as tolerated based on the following: If receiving 0.5 mg dosage, increase to 1 mg once daily; if receiving 1 mg dosage, increase to 2 mg once daily; if receiving 2 mg dose, increase to 3 mg once daily. Maximum daily dose: 3 mg/<b>day</b>. <b>Note: </b>Weight loss target in clinical trials was 1 to 2 kg/week and dosages were adjusted no more frequently than every 2 weeks (Clément 2020). Discontinue therapy if ≥5% of baseline body weight or 5% of baseline BMI has not been lost after 12 to 16 weeks of therapy.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Dosage not tolerated</i>: If receiving the 1 mg dosage, reduce to 0.5 mg once daily; if receiving the 2 mg dosage, reduce to 1 mg once daily; if receiving the 3 mg dosage, reduce to 2 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥12 years and Adolescents: SUBQ: Initial: 2 mg once daily for 2 weeks, then adjust dosage based on efficacy and tolerability as follows:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Additional weight loss desired</i>: Increase dose as tolerated based on the following: If receiving 1 mg dosage, increase to 2 mg once daily; if receiving 2 mg dosage, increase to 3 mg once daily. Maximum daily dose: 3 mg/<b>day</b>. <b>Note:</b> Weight loss target in clinical trials was 1 to 2 kg/week and dosages were adjusted no more frequently than every 2 weeks (Clément 2020). Discontinue therapy if ≥5% of baseline body weight or 5% baseline BMI has not been lost after 12 to 16 weeks of therapy.</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Dosage not tolerated</i>: If receiving the 2 mg dosage, reduce to 1 mg once daily; if receiving the 3 mg dosage, reduce to 2 mg once daily.</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F55173086"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mild to moderate impairment</i> (eGFR ≥30 mL/minute/1.73 m<sup>2</sup>): Children ≥6 years and Adolescents: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Severe impairment</i> (eGFR 15 to 29 mL/minute/1.73 m<sup>2</sup>):</p>
<p style="text-indent:-2em;margin-left:6em;">Children 6 to &lt;12 years: Use is not recommended.</p>
<p style="text-indent:-2em;margin-left:6em;">Children ≥12 years and Adolescents: SUBQ: Initial: 0.5 mg once daily for 2 weeks; if tolerated, increase the dose to 1 mg once daily; if tolerated for at least 1 week, increase dose to 1.5 mg once daily as maintenance dose. Discontinue therapy if any dose not tolerated.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>End-stage renal disease</i> (eGFR &lt;15 mL/minute/1.73 m<sup>2</sup>): Children ≥6 years and Adolescents: Use is not recommended.</p></div>
<div class="block dohp drugH1Div" id="F55173087"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doa drugH1Div" id="F55198099"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="130245" href="/d/html/130245.html" rel="external">see "Setmelanotide: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="24267291-50a0-4efc-98cd-a5840a223299">Weight management, chronic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Weight management, chronic:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For use only in patients with obesity due to Bardet-Biedl syndrome (BBS), or due to pro-opiomelanocortin (<i>POMC)</i>, proprotein convertase subtilisin/kexin type 1 (<i>PCSK1)</i>, or leptin receptor (<i>LEPR)</i> deficiency confirmed by genetic testing demonstrating variants in <i>POMC</i>, <i>PCSK1</i>, or <i>LEPR</i> genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance.</p>
<p style="text-indent:-2em;margin-left:4em;">US labeling:</p>
<p style="text-indent:-2em;margin-left:6em;">Initial: <b>SUBQ:</b> 2 mg once daily for 2 weeks, then adjust dosage as follows:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Initial dosage tolerated</i>: <b>SUBQ:</b> Increase to the target dose of 3 mg once daily; maximum dose: 3 mg/day. If the 3 mg/day dose is not tolerated, decrease to 2 mg once daily. <b>Note</b>: Weight loss target in clinical trials was 2 to 3 kg per week (Clément 2020; Haws 2020).</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Initial dosage not tolerated</i>: <b>SUBQ:</b> Decrease to 1 mg once daily. If the 1 mg/day dose is tolerated for ≥1 week, increase to 2 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">Duration of therapy:</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patients with BBS</i>: Evaluate weight loss after 1 year; continue therapy only if satisfactory weight loss (eg, ≥5% of baseline body weight) has occurred.</p>
<p style="text-indent:-2em;margin-left:8em;">
<i>Patients with POMC, PCSK1, or LEPR deficiency</i>: Evaluate weight loss after 12 to 16 weeks; continue therapy only if satisfactory weight loss (eg, ≥5% of baseline body weight or [in patients with continued growth potential] ≥5% of baseline BMI) has occurred.</p>
<p style="text-indent:-2em;margin-left:4em;">Canadian labeling: <b>SUBQ:</b> 1 mg once daily for 2 weeks, then increase by 0.5 mg daily every 2 weeks as tolerated to a maximum dose of 3 mg/day.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F55198100"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">eGFR ≥30 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">eGFR 15 to &lt;30 mL/minute/1.73 m<sup>2</sup>: Initial: <b>SUBQ:</b> 0.5 mg once daily for 2 weeks, then adjust dosage as follows:</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial dosage tolerated</i>: Increase to 1 mg once daily; if the 1 mg/day dose is tolerated for ≥1 week, increase further to the target dose of 1.5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Initial dosage not tolerated</i>: Discontinue setmelanotide if the 0.5 mg/day dose is not tolerated.</p>
<p style="text-indent:-2em;margin-left:2em;">eGFR &lt;15 mL/minute/1.73 m<sup>2</sup>: Use is not recommended.</p></div>
<div class="block doha drugH1Div" id="F55198101"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block arsc drugH1Div" id="F55714718"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Depression and suicidal ideation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">New or worsened <b>depression</b> or <b>suicidal ideation</b> may occur; serious adverse events of depression, major depression, and suicidal ideation were reported in clinical trials (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33137293']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33137293'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• History of depression (patients with a history of severe depression were excluded from clinical trials)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Disturbance in sexual arousal</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Sexual adverse reactions, particularly those related to disturbances in sexual arousal (eg, spontaneous erections, priapism, labial hypersensitivity, <b>female sexual disorder</b>), may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Setmelanotide is a melanocortin 4 receptor (MC4R) agonist; sympathetic activation of MC4R has been associated with activation of sexual arousal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31100979']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31100979'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reaction</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Severe hypersensitivity reactions</b>, including<b> anaphylaxis</b>, have been reported with setmelanotide.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; generally reported within minutes to hours after injection.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Skin hyperpigmentation</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Increased <b>skin hyperpigmentation</b>, skin discoloration, and darkening of preexisting nevi commonly occurred in clinical trials (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33137293','lexi-content-ref-27468060']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33137293','lexi-content-ref-27468060'])">Ref</a></span>); effect is reversible upon drug discontinuation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Melanocortin receptors and their accessory proteins are involved in a number of endocrine pathways. Setmelanotide, a melanocortin 4 receptor agonist (MC4R), which plays a role in the anorexic effect of leptin, may also act on skin melanocortin 1 receptors (MC1R), which are expressed in the skin and regulate skin pigmentation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33137293','lexi-content-ref-27468060','lexi-content-ref-29678289']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33137293','lexi-content-ref-27468060','lexi-content-ref-29678289'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F55154632"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults and pediatrics.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, hyperpigmentation (including hair discoloration, melanocytic nevus, and skin hyperpigmentation), skin rash, xeroderma</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, constipation, diarrhea, nausea, vomiting, xerostomia</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Spontaneous erections</p>
<p style="text-indent:-2em;margin-left:4em;">Local: Injection-site reaction</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia, chills, depression, dizziness, fatigue, headache, insomnia, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, back pain, limb pain, muscle spasm</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Flu-like symptoms, upper respiratory tract infection</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Atrophic striae</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Female sexual disorder</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aggressive behavior</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Nervous system: Suicidal ideation</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing: Hypersensitivity: Severe hypersensitivity reaction (including anaphylaxis)</p></div>
<div class="block coi drugH1Div" id="F55150232"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Serious hypersensitivity (eg, anaphylaxis) to setmelanotide or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F55198067"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Diluent may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity ("gasping syndrome") in neonates; the "gasping syndrome" consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggest that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p></div>
<div class="block foc drugH1Div" id="F55317408"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous, as acetate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Imcivree: 10 mg/mL (1 mL) [contains benzyl alcohol, edetate (edta) disodium dihydrate, phenol]</p></div>
<div class="block geq drugH1Div" id="F55317406"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F55430190"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Imcivree Subcutaneous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg/mL (per mL): $4,118.40</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F58519047"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Subcutaneous, as acetate: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Imcivree: 10 mg/mL (1 mL) [contains benzyl alcohol, edetate (edta) disodium dihydrate, phenol]</p></div>
<div class="block admp drugH1Div" id="F55173088"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">SUBQ: For SUBQ use <b>only</b>; do <b>not</b> administer IV or IM. Remove from refrigerator ~15 minutes prior to administration, or warm vial by rolling gently between the palms of the hands for 60 seconds. The solution should be clear to slightly opalescent, colorless to slightly yellow; discard if discolored or contains particulate matter. Administer at the beginning of the day (once daily) without regard to meals. Inject into the abdomen, thigh, or arm; rotate injection site daily.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed doses</i>: If a dose is missed, resume once-daily regimen with the next schedule dose.</p></div>
<div class="block adm drugH1Div" id="F55198102"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>SUBQ:</b> For SUBQ use <b>only</b>; do <b>not</b> administer IV or IM. Remove from refrigeration ~15 minutes prior to administration, or warm vial by rolling gently between the palms of the hands for 60 seconds. The solution should be clear to slightly opalescent, colorless to slightly yellow; discard if discolored or contains particulate matter. Administer at the beginning of the day (once daily) without regard to meals. Inject into the abdomen, thigh, or arm; rotate injection site daily. <b>Note:</b> Canadian labeling states for injection into the abdomen only.</p></div>
<div class="block sts drugH1Div" id="F55198069"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store intact vials at 2°C to 8°C (36°F to 46°F). If removed from the refrigerator, intact vials may be kept at 2°C to 25°C (36°F to 77°F) for up to 30 days. Once opened (in use) store at 2°C to 25°C (36°F to 77°F) for up to 30 days. Brief excursions up to 30°C (86°F) are permitted for intact or in use vials. Discard and do not use if exposed to temperatures &gt;30°C (86°F) at any time.</p></div>
<div class="block usep drugH1Div" id="F55150512"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">For chronic weight management in patients with obesity due to Bardet-Biedl syndrome (BSS) or proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency confirmed by genetic testing demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS) (FDA approved in ages ≥6 years and adults).</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Patients with obesity due to suspected POMC, PCSK1, or LEPR deficiency with POMC, PCSK1, or LEPR variants classified as benign or likely benign; other types of obesity not related to BSS or POMC, PCSK1, or LEPR deficiency, including obesity associated with other genetic syndromes and general (polygenic) obesity.</p></div>
<div class="block mst drugH1Div" id="F55198063"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Imcivree may be confused with emicizumab.</p>
<p style="text-indent:0em;margin-left:2em;">Setmelanotide may be confused with melatonin, semaglutide.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F55194906"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F55194903"><span class="drugH1">Drug Interactions</span>
<br/><br/><div class="clear"></div><p style="text-indent:0em;display:inline">There are no known significant interactions.</p></div>
<div class="block rep_considerations drugH1Div" id="F55198065"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Setmelanotide may be associated with adverse sexual reactions in males and females. Spontaneous penile erections may occur in males; patients experiencing an erection lasting &gt;4 hours should seek emergency medical attention. Adverse reactions reported in females include disturbed sexual arousal and hypersensitivity of the labia.</p>
<p style="text-indent:0em;margin-top:2em;">Obesity increases the risk of infertility. Optimal weight control prior to conception improves pregnancy outcomes. However, medications for weight loss are not recommended prior to pregnancy due to safety issues and adverse events. Weight loss medications should be discontinued prior to conception (ACOG 2021; Wharton 2020).</p></div>
<div class="block pri drugH1Div" id="F55198064"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Setmelanotide contains benzyl alcohol as a preservative; although fetal exposure is unlikely, benzyl alcohol is known to cause adverse reactions in premature neonates and low birth weight infants.</p>
<p style="text-indent:0em;margin-top:2em;">An increased risk of adverse maternal and fetal events is associated with obesity. However, moderate gestational weight gain based on pre-pregnancy BMI is required for positive fetal outcomes in all pregnancies, including patients with overweight or obesity. Therefore, medications for weight loss therapy are not recommended during pregnancy (ACOG 2021; Wharton 2020).</p></div>
<div class="block mopp drugH1Div" id="F55173089"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor weight loss periodically and after 12 to 16 weeks of therapy; monitor for appropriate growth and maturation in pediatric patients; monitor for new or worsened depression; monitor skin for changes in hyperpigmentation prior to initiation and periodically thereafter.</p></div>
<div class="block pha drugH1Div" id="F55198090"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Setmelanotide acetate is an 8 amino acid cyclic peptide analog of endogenous melanocortin peptide alpha-melanocyte stimulating hormone, and primarily acts as a melanocortin 4 (MC4) receptor agonist (20-fold greater activity at MC4 compared to melanocortin 3 and melanocortin 1 receptors). MC4 receptors in the brain are involved in regulation of hunger, satiety, and energy expenditure. In patients with obesity due to proopiomelanocortin, proprotein convertase subtilisin/kexin type 1, leptin receptor deficiency, or Bardet-Biedl syndrome associated with insufficient activation of the MC4 receptor, setmelanotide may reestablish MC4 receptor pathway activity to reduce hunger and promote weight loss through decreased caloric intake and increased energy expenditure. Nonclinical evidence shows that MC4 receptors are important for setmelanotide-regulated appetite and weight loss.</p></div>
<div class="block phk drugH1Div" id="F55198091"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 48.7 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 79.1%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Metabolized into small peptides by catabolic pathways.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~11 hours; Terminal half-life: 12.8 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 8 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine: ~39% as unchanged drug.</p>
<p style="text-indent:-2em;margin-left:4em;">Clearance: 4.86 L/hour.</p></div>
<div class="block phksp drugH1Div" id="F55173065"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: AUC increased by 13% to 15%, 34% to 35%, and 86% to 96% in patients with mild, moderate, and severe renal impairment, respectively.</p>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: In pharmacokinetic modeling studies, C<sub>max</sub> was 92% higher in ages 6 to &lt;12 years, and 37% higher in ages 12 to &lt;17 years compared to those ≥17 years of age. AUC was 100% higher in ages 6 to &lt;12 years, and 44% higher in ages 12 to &lt;17 years compared to those ≥17 years of age.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F56522223"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Imcivree</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Imcivree</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Imcivree</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Imcivree</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Imcivree</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Imcivree</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319. doi:10.1067/mpd.2001.116281<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/setmelanotide-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34011890">
<a name="34011890"></a>American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins–Obstetrics. ACOG Practice Bulletin No. 230: Obesity in pregnancy. <i>Obstet Gynecol</i>. 2021;137(6):e128-e144. doi:10.1097/AOG.0000000000004395<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/setmelanotide-pediatric-drug-information/abstract-text/34011890/pubmed" id="34011890" target="_blank">34011890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-CDC.1">
<a name="CDC.1"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol--United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/setmelanotide-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33137293">
<a name="33137293"></a>Clément K, van den Akker E, Argente J, et al; Setmelanotide POMC and LEPR Phase 3 Trial Investigators. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. <i>Lancet Diabetes Endocrinol</i>. 2020;8(12):960-970. doi:10.1016/S2213-8587(20)30364-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/setmelanotide-pediatric-drug-information/abstract-text/33137293/pubmed" id="33137293" target="_blank">33137293</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32627316">
<a name="32627316"></a>Haws R, Brady S, Davis E, et al. Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome. <i>Diabetes Obes Metab</i>. 2020;22(11):2133-2140. doi:10.1111/dom.14133<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/setmelanotide-pediatric-drug-information/abstract-text/32627316/pubmed" id="32627316" target="_blank">32627316</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Imcivree.1">
<a name="Imcivree.1"></a>Imcivree (setmelanotide) [prescribing information]. Boston, MA; Rhythm Pharmaceuticals Inc; November 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Imcivree.2">
<a name="Imcivree.2"></a>Imcivree (setmelanotide) [product monograph]. Mississauga, Ontario, Canada; Q&amp;C Services; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278. doi:10.1542/peds.99.2.268<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/setmelanotide-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27468060">
<a name="27468060"></a>Kühnen P, Clément K, Wiegand S, et al. Proopiomelanocortin deficiency treated with a melanocortin-4 receptor agonist. <i>N Engl J Med</i>. 2016;375(3):240-246. doi:10.1056/NEJMoa1512693<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/setmelanotide-pediatric-drug-information/abstract-text/27468060/pubmed" id="27468060" target="_blank">27468060</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29678289">
<a name="29678289"></a>Novoselova TV, Chan LF, Clark AJ. Pathophysiology of melanocortin receptors and their accessory proteins. <i>Best Pract Res Clin Endocrinol Metab</i>. 2018;32(2):93-106. doi:10.1016/j.beem.2018.02.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/setmelanotide-pediatric-drug-information/abstract-text/29678289/pubmed" id="29678289" target="_blank">29678289</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31100979">
<a name="31100979"></a>Sharma S, Garfield AS, Shah B, et al. Current mechanistic and pharmacodynamic understanding of melanocortin-4 receptor activation. <i>Molecules</i>. 2019;24(10):1892. doi:10.3390/molecules24101892<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/setmelanotide-pediatric-drug-information/abstract-text/31100979/pubmed" id="31100979" target="_blank">31100979</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32753461">
<a name="32753461"></a>Wharton S, Lau DCW, Vallis M, et al. Obesity in adults: a clinical practice guideline. <i>CMAJ</i>. 2020;192(31):E875-E891. doi:10.1503/cmaj.191707<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/setmelanotide-pediatric-drug-information/abstract-text/32753461/pubmed" id="32753461" target="_blank">32753461</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 130246 Version 49.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
